One Rock Capital Partners has sold Kova International, a leading developer of in vitro diagnostic products, to LGC Group, marking a strategic transition aimed at further growth and innovation in the diagnostics market.

Information on the Target

Kova International, Inc. ("Kova" or the "Company") is a prominent developer, manufacturer, and marketer of in vitro diagnostic products tailored for clinical laboratories. Headquartered in Garden Grove, California, Kova specializes in two principal product lines: urinalysis controls that encompass urine-based controls for both urine chemistry and microscopy urinalysis, and toxicology controls, which include urine- and saliva-based controls suited for drug screening and confirmation testing. The Company has established a strong reputation for its high-quality products, catering to significant healthcare clients across North America and internationally.

Previously part of Hycor Biomedical, Kova has adopted the KOVA® brand and has secured its position as a key player in the diagnostics industry. With a focus on innovation and product development, Kova seeks to meet the growing demand for reliable diagnostic solutions in the healthcare sector.

Industry Overview in the Target’s Specific Country

The in vitro diagnostics (IVD) market in the United States is robust and continuously evolving, driven by advancements in technology and increasing prevalence of chronic and infectious diseases. According to market